AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18654870 — intervention group
Group type: COMPARATOR
Intervention: Sixfold diluted smallpox vaccine
Number of subjects: 104
Study 18654870 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 104
Study 15971472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol combination via Diskus (n = 39) for 1 year
Number of subjects: 78
Study 15971472 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (n = 39)
Number of subjects: 78
Study 12647930 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC) over 24.31 days (SD 7.24) for a total of 29.76 hours (SD 12.86)
Number of subjects: 70
Study 12647930 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC)
Number of subjects: 70
Study 10556107 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha(1)‐antitrypsin infusion (250 mg/kg)
Number of subjects: 56
Study 10556107 — intervention group
Group type: COMPARATOR
Intervention: albumin infusion (625 mg/kg)
Number of subjects: 56
Study 8818828 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral co‐trimoxazole 960 mg od or three times a week for primary and secondary prophylaxis
Number of subjects: 0
Study 8818828 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐trimoxazole 120 mg/kg/day in divided doses for 21 days
Number of subjects: 0
Study 8818828 — intervention group
Group type: EXPERIMENTAL
Intervention: IV pentamidine for severe disease
Number of subjects: 0
Study 8818828 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dapsone with trimethoprim, oral clindamycin with primaquine, or IV pentamidine for mild or moderately severe disease
Number of subjects: 0
Study 8818828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant glucocorticoids
Number of subjects: 0
Study 1823530 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics alone
Number of subjects: 759
Study 1823530 — intervention group
Group type: COMPARATOR
Intervention: Untreated hypertension
Number of subjects: 759
Study 6827129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen protection during UVB irradiation
Number of subjects: 0
Study 6827129 — intervention group
Group type: COMPARATOR
Intervention: UVB irradiation without sunscreen
Number of subjects: 0
Study 30638484 — intervention group
Group type: EXPERIMENTAL
Intervention: Far-infrared radiation (FIR)
Number of subjects: 40
Study 30638484 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 29049303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra virgin olive oil and pistachios (IG)
Number of subjects: 1000
Study 29049303 — intervention group
Group type: COMPARATOR
Intervention: Standard diet with limited fat intake (CG)
Number of subjects: 1000
Study 27035157 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory focused cognitive remediation (Brain Fitness)
Number of subjects: 120
Study 27035157 — intervention group
Group type: COMPARATOR
Intervention: Control (nonspecific video games)
Number of subjects: 120
Study 24487087 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial shunt (diameter up to 12 mm)
Number of subjects: 2
Study 24487087 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial shunt (diameter of 8-9 mm)
Number of subjects: 2
Study 24487087 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial shunt
Number of subjects: 2
Study 23484334 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose Rifampicin, Ofloxacin and Minocycline (ROM)
Number of subjects: 1526
Study 23484334 — intervention group
Group type: COMPARATOR
Intervention: WHO-PB-MDT
Number of subjects: 1526
Study 19540162 — intervention group
Group type: EXPERIMENTAL
Intervention: LBC combined with HPV testing (revealed)
Number of subjects: 24510
Study 19540162 — intervention group
Group type: COMPARATOR
Intervention: LBC combined with HPV testing (concealed)
Number of subjects: 24510
Study 17638804 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefmetazole just before skin incision
Number of subjects: 377
Study 17638804 — intervention group
Group type: COMPARATOR
Intervention: Three doses of cefmetazole (1 dose just before skin incision and 2 additional doses every 8 hours)
Number of subjects: 377
Study 15047650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin therapy (vitamins C and E)
Number of subjects: 299
Study 15047650 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 299
Study 12186248 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week skill-oriented program with increasing self-testing activities
Number of subjects: 45
Study 12186248 — intervention group
Group type: COMPARATOR
Intervention: Regular 12-week physical education school program
Number of subjects: 45
Study 9796323 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PTCA
Number of subjects: 0
Study 9796323 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolytic therapy
Number of subjects: 0
Study 9796323 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated Palmaz-Schatz stent
Number of subjects: 0
Study 9796323 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 0
Study 8000624 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 301
Study 8000624 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 301
Study 3189203 — intervention group
Group type: EXPERIMENTAL
Intervention: Girth measurements (mean abdomen, buttocks, right thigh)
Number of subjects: 156
Study 3189203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation of girth measurement equations
Number of subjects: 156
Study 29618280 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) for 16 weeks
Number of subjects: 10
Study 29618280 — intervention group
Group type: COMPARATOR
Intervention: Stretching control for 16 weeks
Number of subjects: 10
Study 31079533 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphate (measured as per SD increment)
Number of subjects: 10612
Study 31079533 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phosphate (assessed as quartiles)
Number of subjects: 10612
Study 28497384 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg cycling (continuous at 50% PPO)
Number of subjects: 12
Study 28497384 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg cycling (interval at 65% PPO and 20% PPO)
Number of subjects: 12
Study 28497384 — intervention group
Group type: COMPARATOR
Intervention: Double-leg cycling (interval and continuous)
Number of subjects: 12
Study 25451627 — intervention group
Group type: EXPERIMENTAL
Intervention: Jyoti meditation (8-week program with weekly 90-minute classes)
Number of subjects: 89
Study 25451627 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program (control group)
Number of subjects: 89
Study 25451627 — intervention group
Group type: EXPERIMENTAL
Intervention: Jyoti meditation
Number of subjects: 89
Study 23331510 — intervention group
Group type: EXPERIMENTAL
Intervention: 600,000 IU of Intramuscular vitamin D3
Number of subjects: 259
Study 23331510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 21702900 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) - 24 IU intranasal administration
Number of subjects: 24
Study 21702900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17977662 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine 6 mg (total 48 mg over 4 days)
Number of subjects: 61
Study 17977662 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 61
Study 16671426 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (Craniotomy for evacuation)
Number of subjects: 530
Study 16671426 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 530
Study 12634590 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole for 28 days (Group A)
Number of subjects: 122
Study 12634590 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole for 7 days (Group B)
Number of subjects: 122
Study 10781452 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol group (goal-oriented hemodynamic therapy)
Number of subjects: 403
Study 10781452 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 403
Study 8630614 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg terbutaline sulphate via Turbuhaler (TBH)
Number of subjects: 13
Study 8630614 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg terbutaline sulphate via pMDI
Number of subjects: 13
Study 8630614 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg terbutaline sulphate via pMDI
Number of subjects: 13
Study 8630614 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline sulphate via Turbuhaler (TBH)
Number of subjects: 13
Study 1477308 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg dose of trihexyphenidyl
Number of subjects: 20
Study 1477308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6398984 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g Na (44 mmol) daily diet
Number of subjects: 65
Study 6398984 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 65
Study 3539897 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron therapy (d(15)+Be neutrons)
Number of subjects: 0
Study 3539897 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy (megavoltage photons)
Number of subjects: 0
Study 29644408 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-driven maintenance therapy
Number of subjects: 0
Study 29644408 — intervention group
Group type: COMPARATOR
Intervention: Standard induction treatment
Number of subjects: 0
Study 26554630 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol PR 50 mg (titrated to maximum 250 mg)
Number of subjects: 0
Study 26554630 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone/naloxone PR 10 mg/5 mg (titrated to maximum 40 mg/20 mg plus oxycodone PR 10 mg)
Number of subjects: 0
Study 25689521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Construal Level (self decision-making)
Number of subjects: 768
Study 25689521 — intervention group
Group type: COMPARATOR
Intervention: High Construal Level (advising others)
Number of subjects: 768
Study 25689521 — intervention group
Group type: EXPERIMENTAL
Intervention: Saving 5 people
Number of subjects: 768
Study 25689521 — intervention group
Group type: EXPERIMENTAL
Intervention: Saving 15 people
Number of subjects: 768
Study 25689521 — intervention group
Group type: EXPERIMENTAL
Intervention: Trolley problem
Number of subjects: 768
Study 25689521 — intervention group
Group type: EXPERIMENTAL
Intervention: Footbridge problem
Number of subjects: 768
Study 23933108 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Behavior Therapy for Selective Mutism (IBTSM)
Number of subjects: 21
Study 23933108 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 21
Study 20462395 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amphotericin B (0.2 mg/mL) eye drops every 2 hours for 21 days and subconjunctival fluconazole (2 mg/mL) injections
Number of subjects: 12
Study 18405818 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction therapy (removal of 4 premolars)
Number of subjects: 26
Study 18405818 — intervention group
Group type: COMPARATOR
Intervention: Nonextraction therapy with air-rotor stripping (ARS)
Number of subjects: 26
Study 16606473 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus streptomycin
Number of subjects: 31
Study 16606473 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin plus rifampicin
Number of subjects: 31
Study 14633755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg every 4 h for 24 h)
Number of subjects: 201
Study 14633755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 14633755 — intervention group
Group type: COMPARATOR
Intervention: Nefopam and Placebo
Number of subjects: 201
Study 10724301 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol delivered via reservoir DPI (Clickhaler)
Number of subjects: 0
Study 10724301 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol delivered via conventional pressurized metered-dose inhaler (MDI)
Number of subjects: 0
Study 8842961 — intervention group
Group type: EXPERIMENTAL
Intervention: Epineurotomy
Number of subjects: 86
Study 8842961 — intervention group
Group type: COMPARATOR
Intervention: Nonepineurotomy
Number of subjects: 86
Study 1523534 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% podophyllotoxin cream
Number of subjects: 60
Study 1523534 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60
Study 6385444 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg trimethoprim
Number of subjects: 260
Study 6385444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 30712923 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg once daily
Number of subjects: 97
Study 30712923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 29086085 — intervention group
Group type: COMPARATOR
Intervention: OnTrack
Number of subjects: 230
Study 29086085 — intervention group
Group type: COMPARATOR
Intervention: Onco-Move
Number of subjects: 230
Study 26825020 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion-Controlled Meals (PCM)
Number of subjects: 0
Study 26825020 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Treatment (ABT)
Number of subjects: 0
Study 26825020 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 23274083 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamigex (essential oils from Syzygium aromaticum, Lavandula angustifolia, and Geranium robertianum)
Number of subjects: 70
Study 23274083 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 0.3%
Number of subjects: 70
Study 22182296 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT) plus ongoing routine clinical care (RCC)
Number of subjects: 50
Study 22182296 — intervention group
Group type: COMPARATOR
Intervention: Routine Clinical Care (RCC) alone
Number of subjects: 50
Study 20824976 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil supplementation (20 mL daily) during late pregnancy and first six months of lactation
Number of subjects: 499
Study 18821156 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (XO inhibitor)
Number of subjects: 9
Study 18821156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15822806 — intervention group
Group type: EXPERIMENTAL
Intervention: Deformable model‐based segmentation of lumen and thrombus using a grey level model and k‐nearest neighbors classification
Number of subjects: 17
Study 12529568 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced interventions
Number of subjects: 0
Study 12529568 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 12529568 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced programs
Number of subjects: 0
Study 9642600 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (Group 1) with bupivacaine 0.75% and intravenous midazolam and fentanyl.
Number of subjects: 90
Study 9642600 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia (Group 2) with intravenous methohexital followed by retrobulbar block with an equal mixture of lidocaine 2% and bupivacaine 0.75% plus hyaluronidase 150 units.
Number of subjects: 90
Study 9642600 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (Group 1)
Number of subjects: 90
Study 9642600 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia (Group 2)
Number of subjects: 90
Study 7506007 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-lead electrocardiograms
Number of subjects: 4674
Study 7506007 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute rhythm strips
Number of subjects: 4674
Study 7506007 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-lead ECG
Number of subjects: 4674
Study 7506007 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum potassium < 3.5 mmol/L
Number of subjects: 4674
Study 2554357 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic delta sleep‐inducing peptide (DSIP) (25 nmol/kg BW)
Number of subjects: 11
Study 2554357 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 11
Study 2554357 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic delta sleep‐inducing peptide (DSIP)
Number of subjects: 11
Study 351600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludilat (3 tablets per day for 3 months)
Number of subjects: 75
Study 351600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same duration as Fludilat)
Number of subjects: 75
Study 30931761 — intervention group
Group type: EXPERIMENTAL
Intervention: White patient condition
Number of subjects: 57
Study 30931761 — intervention group
Group type: COMPARATOR
Intervention: Black patient condition
Number of subjects: 57
Study 30931761 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 57
Study 29916929 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TXA (3 g diluted in 45 mL normal saline, applied after cementation)
Number of subjects: 640
Study 29916929 — intervention group
Group type: COMPARATOR
Intervention: IV TXA (1 g prior to tourniquet inflation and 1 g at closure)
Number of subjects: 640
Study 27476803 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Employment
Number of subjects: 116
Study 25501057 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 161
Study 25501057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 22252528 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief telephonic program to improve work functioning
Number of subjects: 79
Study 22252528 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 79
Study 19463847 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular unspaced sentences
Number of subjects: 0
Study 19463847 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternatingbold unspaced sentences
Number of subjects: 0
Study 19463847 — intervention group
Group type: COMPARATOR
Intervention: Normally written sentences
Number of subjects: 0
Study 17258423 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 1.5 mg/kg
Number of subjects: 67
Study 15153576 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of blood pressure and volume, regulated metabolic and clinical indices
Number of subjects: 155
Study 15153576 — intervention group
Group type: COMPARATOR
Intervention: Initial normal LV indices
Number of subjects: 155
Study 15153576 — intervention group
Group type: COMPARATOR
Intervention: Initial LV hypertrophy
Number of subjects: 155
Study 12241831 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional strategy (angiography followed by revascularisation)
Number of subjects: 1810
Study 12241831 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (ischaemia-driven or symptom-driven angiography)
Number of subjects: 1810
Study 12241831 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional strategy
Number of subjects: 1810
Study 12241831 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 1810
Study 9238142 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention group (telephone and mail reminders)
Number of subjects: 256
Study 9238142 — intervention group
Group type: COMPARATOR
Intervention: Regular intervention group (mail reminder only)
Number of subjects: 256
Study 9238142 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention for subjects with no postsecondary education
Number of subjects: 256
Study 9238142 — intervention group
Group type: COMPARATOR
Intervention: Regular intervention for subjects with higher education
Number of subjects: 256
Study 7957495 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected patients with CD4 < 200 mm-3 (groups 1 and 2)
Number of subjects: 95
Study 7957495 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected patients with CD4 < 400 mm-3 (groups 1, 2, 3)
Number of subjects: 95
Study 7957495 — intervention group
Group type: COMPARATOR
Intervention: All HIV-positive patients
Number of subjects: 95
Study 7957495 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients
Number of subjects: 95
Study 3301980 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (200 mg), administered five times per day for 5 days
Number of subjects: 210
Study 3301980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 28857425 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP (30 billion CFUs per sachet, 2 sachets daily for 4 weeks) and omega-3 fatty acid (2 g daily for 8 weeks)
Number of subjects: 140
Study 28857425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 28938980 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure to the P6 pressure point using a wristband for a maximum of 2 hours post-surgery.
Number of subjects: 0
Study 28938980 — intervention group
Group type: COMPARATOR
Intervention: Control group with malpositioned wristbands.
Number of subjects: 0
Study 24767875 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (624 mg once daily for 6 months)
Number of subjects: 34
Study 24767875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 6 months)
Number of subjects: 34
Study 23617712 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention
Number of subjects: 70
Study 23617712 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 19773525 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide (2.5 to 80 mg, daily subcutaneous administration)
Number of subjects: 256
Study 17868680 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-based physical activity intervention program
Number of subjects: 2929
Study 17868680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2929
Study 17167156 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (PA) intervention
Number of subjects: 424